Novel Scoring System Can Up Access to Biologics in Psoriasis

Share this content:
DLQI-R allows more patients to achieve threshold for becoming candidates for biologic treatment.
DLQI-R allows more patients to achieve threshold for becoming candidates for biologic treatment.

HealthDay News —  A new scoring system that accounts for "not relevant" responses (NRRs) on the Dermatology Life Quality Index (DLQI) for patients with psoriasis is valid for avoiding bias and can improve access to biologics, according to a study published in the November issue of the British Journal of Dermatology.

Fanni Rencz, MD, PhD, from Corvinus University of Budapest in Hungary, and colleagues proposed a new scoring system for the DLQI that corrects for the bias in the NRR option (DLQI-R) and examined its construct validity using data from 242 patients (104 of whom marked at least 1 NRR). For each patient, the DLQI score was calculated according to the original scoring and by applying the new scoring formula. The DLQI-R validity was tested against the Psoriasis Area and Severity Index (PASI) and the 3-level 5-dimension EuroQoL (EQ-5D-3L).

The researchers found mean scores of 9.99 ± 7.52 and 11.0 ± 8.02 on the DLQI and DLQI-R, respectively. With the DLQI-R score, 8 more patients (3.3%) achieved the "PASI > 10 and DLQI > 10" threshold required by clinical guidelines to become candidates for systemic treatment. When the number of NRRs allowed were limited to 2 or 3, the results were robust. The DLQI-R correlated slightly better with PASI and EQ-5D-3L index scores than the DLQI.

"The novel scoring primarily strives to provide fair access to systemic treatments for patients with psoriasis," the authors write.

Abstract/Full Text (subscription or payment may be required)
Editorial

You must be a registered member of Clinical Advisor to post a comment.

Sign Up for Free e-newsletters